Relypsa Inc (RLYP): David W J Mcgirr , director of Relypsa Inc sold 1,013 shares on Jun 7, 2016. The Insider selling transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were sold at $19.34 per share for a total value of $19,587.98 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 16, 2016, Kristine M Ball (CFO) purchased 7,000 shares at $12.15 per share price.On Mar 16, 2016, Thomas J. Schuetz (director) purchased 30,000 shares at $13.39 per share price.Also, On Jan 4, 2016, Wilhelm Stahl (SVP, Chief Technology Officer) sold 20,000 shares at $28.53 per share price.On Dec 9, 2015, John A Orwin (President & CEO) sold 15,000 shares at $28.68 per share price.
Shares of Relypsa Inc (RLYP) ended Tuesday, Jun 7, 2016 session in red amid volatile trading. The shares closed down -0.91 points or -4.49% at $19.34 with 26,27,354 shares getting traded. Post opening the session at $19.5, the shares hit an intraday low of $19.24 and an intraday high of $19.9 and the price vacillated in this range throughout the day. The company has a market cap of $865 M and the number of outstanding shares has been calculated to be 4,47,47,978 shares. The 52-week high of Relypsa Inc is $36.16 and the 52-week low is $10.26.
Company has been under the radar of several Street Analysts.Relypsa Inc is Downgraded by Morgan Stanley to Underweight. Earlier the firm had a rating of Equal-Weight on the company shares. The Rating was issued on Jun 7, 2016.Relypsa Inc is Upgraded by Mizuho to Neutral and the brokerage firm has raised the Price Target to $ 20 from a previous price target of $12 .Earlier the firm had a rating of Underperform on the company shares. The Rating was issued on Jun 1, 2016.Relypsa Inc is Upgraded by Morgan Stanley to Equal-Weight. Earlier the firm had a rating of Underweight on the company shares. The Rating was issued on May 23, 2016.Relypsa Inc is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 51 from a previous price target of $52 . The Rating was issued on May 9, 2016.Relypsa Inc is Downgraded by Mizuho to Underperform while Lowering the Price Target of the company shares to $ 12 from a previous price target of $22 . Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on May 4, 2016.
Relypsa Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal cardiovascular and metabolic diseases. The Company’s lead product candidate Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration or FDA. The Company’s NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.